Stockreport

Verastem gets FDA orphan drug status for low-grade ovarian cancer therapy [Seeking Alpha]

Verastem, Inc.  (VSTM) 
Last verastem, inc. earnings: 10/29 04:17 pm Check Earnings Report
US:NASDAQ Investor Relations: verastem.com
PDF The orphan drug status was assigned to avutometinib, a RAF/MEK clamp, alone or in combination with defactinib, a selective FAK inhibitor, for the treatment of recurrent [Read more]